跳至主要内容
临床试验/NCT00873340
NCT00873340已完成不适用

Physical Disability Observational Study in Patients Treated With Betaferon in Daily Practice

Bayer0 个研究点目标入组 83 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
83
主要终点
To collect observational local data about effectivity related to physical disability progression on the daily routine basis in patients treated with Betaferon

研究概览

简要总结

To gather Observation data about physical disability progression, safety and adherence during the use of Betaferon in daily practice. Patients with any type of Multiple Sclerosis (MS) (MRRS) (PSMS), under treatment with Betaferon.Open Multicentric Observational study.24 months.Evaluation of physical disability in patients treated with Betaferon, using Kurtzke's expanded disability scale (EDSS) in biannual periods

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be able to join the study.

排除标准

  • Pregnancy
  • Patients with a history of hypersensitivity to natural or recombinant interferon-beta, human albumin or to any of the excipients
  • Patients with a history of severe depressive disorders and/or suicidal ideation
  • Patient with decompensated liver disease
  • Patient with epilepsy not adequately controlled by treatment

研究组 & 干预措施

Group 1

干预措施: Interferon-1beta (Betaseron, BAY86-5046) (Drug)

结局指标

主要结局

To collect observational local data about effectivity related to physical disability progression on the daily routine basis in patients treated with Betaferon

时间窗: Every 6 months for 2 years

次要结局

  • To evaluate Betaferon safety on the daily routine basis(Every 6 months)
  • To evaluate patient adherence to Betaferon treatment(Every 6 months)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验

Physical Disability in Patients Treated With... | 临床试验